John Trizzino appointed Immunovaccine CEO
This article was originally published in Scrip
Executive Summary
Immunovaccine, a vaccine development company, has appointed John Trizzino chief executive officer, effective 1 October 2011. He joins the company from Novavax where he served as senior vice-president. While there, he successfully negotiated profitable joint venture and licensing agreements, including a $179 million contract with the US government to produce influenza vaccines.